Literature DB >> 12627520

Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.

Maria Planck1, Kajsa Ericson, Zofia Piotrowska, Britta Halvarsson, Eva Rambech, Mef Nilbert.   

Abstract

BACKGROUND: Carcinomas of the small intestine are rare, but the risk is greatly increased in patients with hereditary nonpolyposis colorectal cancer (HNPCC) due to an inherited mismatch repair (MMR) gene mutation, most commonly affecting the genes MLH1 or MSH2. Defective MMR is characterized by microsatellite instability (MSI) and loss of MMR protein expression in the tumor tissue. However, a subset of several sporadic tumor types, including about 15% of colon cancers, also evolve through defective MMR.
METHODS: The authors have assessed the frequency of MSI and analyzed the immunohistochemical expression of MLH1 and MSH2 in a population-based series of 89 adenocarcinomas of the small intestine. To study the contribution of MSI and defective MMR protein expression in young patients, 43 cancers of the small intestine from patients below age 60 years (including 24 tumors from the population-based series and an additional 19 tumors from young individuals) were also analyzed.
RESULTS: MSI was detected in 16/89 tumors (18%) in the population-based series, and immunohistochemistry revealed loss of expression for MLH1 in 7/16 MSI tumors and in 2/73 MSS tumors, whereas all tumors showed normal expression for MSH2. Among the young patients, the authors identified MSI in 10/43 tumors (23%), and 6 of these 10 MSI tumors showed immunohistochemical loss of MMR protein expression, which affected MLH1 in 3 cases and MSH2 in 3 cases.
CONCLUSIONS: The frequency of MSI (18%) in adenocarcinomas of the small intestine equals that of colon cancer. However, silencing of MLH1 seems to explain the MSI status in only about half of the MSI tumors. Among patients with cancer of the small intestine before age 60 years, MSI is found in 23% of the cases, with MLH1 and MSH2 being affected at equal frequencies, indicating that HNPCC may underly a subset of such cases. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11197

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627520     DOI: 10.1002/cncr.11197

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.

Authors:  Reiko Kumagai; Kenichi Kohashi; Shunsuke Takahashi; Hidetaka Yamamoto; Minako Hirahashi; Kenichi Taguchi; Kenichi Nishiyama; Yoshinao Oda
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

Review 3.  Germline Variants Impact Somatic Events during Tumorigenesis.

Authors:  Johnny R Ramroop; Madelyn M Gerber; Amanda Ewart Toland
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

4.  A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.

Authors:  Michael J Overman; Chung-Yuan Hu; Scott Kopetz; James L Abbruzzese; Robert A Wolff; George J Chang
Journal:  Ann Surg Oncol       Date:  2011-12-21       Impact factor: 5.344

5.  Atypical identification of Lynch syndrome by immunohistochemistry and microsatellite instability analysis on jejunal adenocarcinoma.

Authors:  D E McIlvried; R E Birhiray; J Z Lu
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

6.  APC mutations are common in adenomas but infrequent in adenocarcinomas of the non-ampullary duodenum.

Authors:  Kenichi Ishizu; Taiki Hashimoto; Tomoaki Naka; Yasushi Yatabe; Motohiro Kojima; Takeshi Kuwata; Satoru Nonaka; Ichiro Oda; Minoru Esaki; Masashi Kudo; Naoto Gotohda; Teruhiko Yoshida; Takaki Yoshikawa; Shigeki Sekine
Journal:  J Gastroenterol       Date:  2021-09-12       Impact factor: 7.527

7.  Recent advances in the management of adenocarcinoma of the small intestine.

Authors:  Michael J Overman
Journal:  Gastrointest Cancer Res       Date:  2009-05

Review 8.  Small bowel adenocarcinomas--existing evidence and evolving paradigms.

Authors:  Kanwal Raghav; Michael J Overman
Journal:  Nat Rev Clin Oncol       Date:  2013-07-30       Impact factor: 66.675

Review 9.  Primary small bowel adenomas and adenocarcinomas-recent advances.

Authors:  Aoife Maguire; Kieran Sheahan
Journal:  Virchows Arch       Date:  2018-07-11       Impact factor: 4.064

10.  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Authors:  M J Overman; J Pozadzides; S Kopetz; S Wen; J L Abbruzzese; R A Wolff; H Wang
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.